In such study among 42 patients with different solid tumors evaluated with immunohistochemical analysis, none of those with PD-L1 negative tumor obtained an ORR, while about one third of patients with PD-L1 positive tumors had a clinical response. This evidence concerns the gene CD274 and neoplasm.